Coexistence of p210 and CBFβ-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.

Numerous acquired molecular and cytogenetic abnormalities are strongly associated with hematological malignancies. The breakpoint cluster region-ABL proto-oncogene 1 () rearrangement leads to a p210 chimeric protein in typical chronic myeloid leukemia (CML), whereas 17-25% of patients with acute lymphocytic leukemia and 0.9-3% patients with acute myeloid leukemia (AML) carry a p190 fusion protein. Cases of patients with AML/CML carrying two specific primary molecular changes, and core binding factor-β-myosin heavy chain 11 () fusion genes have been rarely reported. The present study aimed to understand the nature and mechanism of this particular type of leukemia through case reports and literature review. A total of four patients who were diagnosed as AML/CML with and fusion genes in the First Affiliated Hospital of Soochow University (Suzhou, China) between January 2004 and December 2012 were examined. Morphological analysis of bone marrow cells, flow cytometry, quantitative polymerase chain reaction of and transcripts as well as cytogenetic and fluorescence hybridization analyses were performed. A total of 4 patients who exhibited fusion of and were identified. A single patient (case 1) was first diagnosed CML-acute phase (AP), which progressed rapidly to CML-blast crisis (BC), and three patients (cases 2, 3 and 4) were diagnosed with AML with bone marrow eosinophilia at first presentation with no evidence of previous onset of CML. All cases achieved remission following conventional chemotherapy/hematological stem cell transplantation combined with the inhibitor of tyrosine kinase (TKI) maintenance therapy. The patients with CML carrying and expressing and fusion genes appeared more likely to rapidly progress to AP or BC. Therefore, the product of the fusion gene may serve an important role in the transformation of CML. The co-expression of p and fusion genes in myeloid leukemia may be a molecular event occurring not only during the development of CML, but also in AML.